Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expanded-access for the Use of Setmelanotide in a Single Patient With Partial Lipodystrophy (LD) Associated With Leptin Deficiency and Multiple Autoimmune Diseases

NCT03262610 is registered in ClinicalTrials.gov with Rhythm Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03262610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03262610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expanded-access for the Use of Setmelanotide in a Single Patient With Partial Lipodystrophy (LD) Associated With Leptin Deficiency and Multiple Autoimmune Diseases
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 15, 2017
Completion date
January 31, 2018
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertriglyceridemia, obesity